摘要
目的:系统评价屈昔多巴治疗神经源性直立性低血压的有效性及安全性,为临床实践提供循证医学证据。方法:计算机检索PubMed、EMbase、MEDLINE、Cochran Library、CNKI、维普、万方等数据库,查找屈昔多巴治疗神经源性直立性低血压的随机对照试验,根据Cochrane系统评价方法对检索到的文献进行筛选、数据提取和文献质量评估,然后采用RevMan5.2软件进行Meta分析。结果:共纳入4个RCT研究,合计461例患者。Meta分析结果显示:屈昔多巴组OHQ综合评分低于安慰剂组,差异有统计学意义[MD=-0.55,95%CI(-0.94,-0.16),P=0.005];屈昔多巴组OHSA综合评分低于安慰剂组,差异有统计学意义[MD=-0.65,95%CI(-1.18,-0.12),P=0.02];屈昔多巴组OHSA评分(头晕/头重脚轻项)低于安慰剂组,差异有统计学意义[MD=-0.76,95%CI(-1.31,-0.22),P=0.49];屈昔多巴组站立位收缩压高于安慰剂组,差异有统计学意义[MD=5.83,95%CI(2.13,9.53),P=0.002];屈昔多巴组不良反应发生率与安慰剂组比较,差异无统计学意义[MD=0.91,95%CI(0.68,1.22),P=0.54]。结论:屈昔多巴能有效治疗神经源性直立性低血压,显著改善患者临床症状,增加患者站立位收缩压,且安全性良好,患者耐受性好。
Objective：To assess the effectivity and safety of Droxidopa for Neurogenic Orthostatic Hypotension and provide evidence for clinical practice.Method：We searched studies from the following databases：PubMed,EMbase,MEDLINE,Cochrane Library,CNKI,VIP and WANFANG.Studies of Randomized controlled trials（RCTs）of Droxidopa for Neurogenic Orthostatic Hypotension were included for quality analysis and meta-analysis.Result：The 4RCTs were included,involving 461 patients.Meta-analysis showed that：The OHQ composite score in Droxidopagroup was better than in placebo group,and the difference between Droxidopagroup and placebo group was statistically significant（MD=-0.55,95%CI[-0.94,-0.16],P=0.005）.The OHSA composite score in Droxidopagroup was better than in placebo group,and the difference between Droxidopagroup and placebo group was statistically significant（MD=-0.65,95%CI[-1.18,-0.12],P=0.02）.Droxidopagroup OHSA score item 1（dizziness/lightheadedness）in droxidopagroup was better than in placebo group,and the difference between Droxidopagroup and placebo group was statistically significant（MD=-0.76,95%CI[-1.31,-0.22],P=0.49）.Droxidopagroup standing systolic blood pressure better than in the placebo group,and the difference between Droxidopagroup and placebo group was statistically significant（MD=4.24,95%CI[0.51,7.98],P=0.03）.The difference of incidence of adverse reactions in droxidopagroup and placebo group was no statistically significant（MD=0.91,95%CI[0.68,1.22],P=0.54）.Conclusion：Compared with placebo,Droxidopa is effective in treating neurogenic orthostatic hypotension and patients was generally well tolerated.
作者
陈昆
肖顺林
黄毅岚
叶云
CHEN Kun XIAO Shunlin HUANG Yilan YE Yun(Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, Chin)
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2016年第11期1092-1097,共6页
Journal of Clinical Cardiology
